Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 10, 2026 | −$0.99 | — | $218.38M | +45.5% | −$0.89 |
| Q1 FY26ended Mar 31, 2026 | May 11, 2026 | −$1.26 | — | $191.20M | +57.4% | −$0.79 |
| Q4 FY25ended Dec 31, 2025 | — | −$0.56 | — | $196.00M | +65.0% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$0.94 | — | $170.99M | +63.2% | — |
| Q2 FY25ended Jun 30, 2025 | — | −$0.97 | — | $150.04M | +72.1% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$1.22 | — | $121.46M | +62.0% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$1.54 | — | $118.77M | +66.0% | — |
| Q3 FY24ended Sep 30, 2024 | — | −$1.34 | — | $104.76M | +81.3% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Axsome Therapeutics shares, not any token. As of Aug 10, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 |
| — |
| −$1.67 |
| — |
| $87.17M |
| — |
| — |
| Q1 FY24ended Mar 31, 2024 | — | −$1.44 | — | $75.00M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$2.08 | — | $71.53M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$1.32 | — | $57.79M | — | — |